The in-vitro antibacterial activity of a combination of cefpirome or cefoperazone with vancomycin against enterococci and Staphylococcus aureus.
Cefpirome, cefoperazone and ceftazidime were tested for their in-vitro activity against Enterococcus faecalis and methicillin-resistant Staphylococcus aureus (MRSA) isolates. Cefpirome was the most active cephalosporin followed by cefoperazone. Ceftazidime had only very limited activity against these strains. In experiments with cefpirome/vancomycin and cefoperazone/vancomycin combinations, synergy was detected against most MRSA strains and some enterococci. Antagonism did not occur.
Seibert
G
G
Hoechst AG, SBU Anti-infectives Research, Frankfurt, Germany.
Isert
D
D
Klesel
N
N
Limbert
M
M
Markus
A
A
Schrinner
E
E
D002438:Cefoperazone / Q000494:pharmacology*; D002511:Cephalosporins / Q000494:pharmacology*; D004359:Drug Therapy, Combination / Q000494:pharmacology; D016983:Enterococcus / Q000187:drug effects*; D016106:Methicillin Resistance; D008826:Microbial Sensitivity Tests; D013211:Staphylococcus aureus / Q000187:drug effects*; D014640:Vancomycin / Q000494:pharmacology*; D000097572:Cefpirome
D002438:Cefoperazone; D002511:Cephalosporins; D014640:Vancomycin; D000097572:Cefpirome